$MDGL
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ร agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Healthcare
Sector
Biotechnology
Industry
William J. Sibold
CEO
528
Employees
$519.09
Current Price
$10.55B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 1 | $341,940.08 | 664 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 11 | $1,710,193.53 | 3,164 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 11 | $1,710,193.53 | 3,164 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | Kelley Shannon T General Counsel | Sale | 664 | $514.97 | $341,940.08 | View Details |
| Jul 20, 2026 | Sibold William John Director | Sale | 269 | $547.08 | $147,164.20 | View Details |
| Jul 20, 2026 | Sibold William John Director | Sale | 47 | $548.87 | $25,796.98 | View Details |
| Jul 20, 2026 | Sibold William John Director | Sale | 140 | $542.75 | $75,984.43 | View Details |
| Jul 20, 2026 | Sibold William John Director | Sale | 545 | $544.71 | $296,869.13 | View Details |
| Jul 20, 2026 | Sibold William John Director | Sale | 275 | $545.71 | $150,070.03 | View Details |
| Jul 20, 2026 | Sibold William John Director | Sale | 280 | $555.05 | $155,414.00 | View Details |
| Jul 20, 2026 | Sibold William John Director | Sale | 153 | $550.01 | $84,152.11 | View Details |
| Jul 20, 2026 | Sibold William John Director | Sale | 110 | $543.79 | $59,817.22 | View Details |
| Jul 20, 2026 | Sibold William John Director | Sale | 680 | $547.70 | $372,434.64 | View Details |
| Jul 20, 2026 | Sibold William John Director | Sale | 1 | $550.72 | $550.72 | View Details |
| Jun 1, 2026 | Soergel David Chief Medical Officer | Sale | 1,042 | $495.74 | $516,561.08 | View Details |
167 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies: